Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation

  • López-Fernández, Adrià|||0000-0002-2844-5998
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Pérez, Eduard
  • Darder, Esther
  • Vallmajó, Anna
  • Cruellas, Mara|||0000-0002-6953-9675
  • Roqué, Ariadna|||0000-0003-0492-7463
  • Cartró, Mireia
  • Carrasco, Estela|||0000-0003-1964-7675
  • Rezqallah, Alejandra
  • Jimenez-Macedo, Ana Raquel
  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Teule, Alex|||0000-0003-0028-7200
  • Munté, Elisabet|||0000-0001-8396-8284
  • Tuset, Noemi|||0000-0001-8432-7059
  • Diez, Orland|||0000-0001-7339-0570
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Llort, Gemma|||0000-0001-9987-7862
  • Carver, Tim|||0000-0003-1508-3091
  • Ficorella, Lorenzo|||0000-0002-0577-1571
  • Mavaddat, Nasim|||0000-0003-0307-055X
  • Mercadé Carceller, Anna|||0000-0002-4714-3565
  • Antoniou, Antonis C.
  • Brunet, Joan|||0000-0003-1945-3512
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Duran-Lozano, Laura
  • Pardo, Mònica
  • Alfonso, Rosa
  • Bareas, Adriana
  • Torres, Maite|||0000-0002-2497-3478
  • López, Consol
Background Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of 2 risk-assessment delivery models. Methods This 2-step study included 663 healthy women with a family history of breast cancer in which no pathogenic variants were identified. First, breast density and PRS were added to the baseline risk assessment for all participants. A randomized intervention study compared 2 delivery models (in-person vs pre-recorded video) for risk assessment in women at moderate or average risk. All tests were 2-sided. Results Breast density and PRS reclassified the risk group into 33% of the participants, with only 5% reclassified as high-risk. After disclosure of their estimated multifactorial risk, 65% of women aligned their risk perception with their estimated risk, compared to 47% at baseline (P <. 05). No statistically significant differences were found in the primary endpoint cancer worry, mean = 10.2 (SD = 3.1) vs 10.1 (2.7), between delivery models. In-person delivery had slightly better psychological outcomes (excluding the primary outcome) and higher satisfaction, though few participants in the video group sought in-person clarification. Conclusions Incorporating breast density and PRS into risk assessments led to substantial reclassification, with 1 in 5 women facing de-escalated surveillance. Personalized assessments improve objective perceptions alignment. A model using a pre-recorded video-based model matches in-person delivery for moderate and average-risk women and is scalable for population-level implementation.
Repisalud
Publication Artículo científico (JournalArticle)

Obtaining EHR-derived datasets for COVID-19 research within a short time: a flexible methodology based on Detailed Clinical Models

  • Pedrera-Jiménez, Miguel
  • García-Barrio, Noelia
  • Cruz-Rojo, Jaime
  • Terriza-Torres, Ana Isabel
  • López-Jiménez, Elena Ana
  • Calvo-Boyero, Fernando
  • Jiménez-Cerezo, María Jesús
  • Blanco-Martínez, Alvar Javier
  • Roig-Domínguez, Gustavo
  • Cruz-Bermúdez, Juan Luis
  • Bernal-Sobrino, José Luis
  • Serrano-Balazote, Pablo
  • Muñoz Carrero, Adolfo
Background: COVID-19 ranks as the single largest health incident worldwide in decades. In such a scenario, electronic health records (EHRs) should provide a timely response to healthcare needs and to data uses that go beyond direct medical care and are known as secondary uses, which include biomedical research. However, it is usual for each data analysis initiative to define its own information model in line with its requirements. These specifications share clinical concepts, but differ in format and recording criteria, something that creates data entry redundancy in multiple electronic data capture systems (EDCs) with the consequent investment of effort and time by the organization. Objective: This study sought to design and implement a flexible methodology based on detailed clinical models (DCM), which would enable EHRs generated in a tertiary hospital to be effectively reused without loss of meaning and within a short time. Material and methods: The proposed methodology comprises four stages: (1) specification of an initial set of relevant variables for COVID-19; (2) modeling and formalization of clinical concepts using ISO 13606 standard and SNOMED CT and LOINC terminologies; (3) definition of transformation rules to generate secondary use models from standardized EHRs and development of them using R language; and (4) implementation and validation of the methodology through the generation of the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC-WHO) COVID-19 case report form. This process has been implemented into a 1300-bed tertiary Hospital for a cohort of 4489 patients hospitalized from 25 February 2020 to 10 September 2020. Results: An initial and expandable set of relevant concepts for COVID-19 was identified, modeled and formalized using ISO-13606 standard and SNOMED CT and LOINC terminologies. Similarly, an algorithm was designed and implemented with R and then applied to process EHRs in accordance with standardized concepts, transforming them into secondary use models. Lastly, these resources were applied to obtain a data extract conforming to the ISARIC-WHO COVID-19 case report form, without requiring manual data collection. The methodology allowed obtaining the observation domain of this model with a coverage of over 85% of patients in the majority of concepts. Conclusion: This study has furnished a solution to the difficulty of rapidly and efficiently obtaining EHR-derived data for secondary use in COVID-19, capable of adapting to changes in data specifications and applicable to other organizations and other health conditions. The conclusion to be drawn from this initial validation is that this DCM-based methodology allows the effective reuse of EHRs generated in a tertiary Hospital during COVID-19 pandemic, with no additional effort or time for the organization and with a greater data scope than that yielded by conventional manual data collection process in ad-hoc EDCs.
Repisalud
Publication Artículo científico (JournalArticle)

ΔNp73 and its effector targets promote colorectal peritoneal carcinosis and predict survival

  • Pastor-Morate, Daniel
  • Amigo-Morán, Lidia
  • Garranzo-Asensio, Maria
  • Rejas-González, Raquel
  • Carnicero, Patricia
  • Rodríguez, Nuria
  • Pérez-Robledo, Juan Pedro
  • Barderas Manchado, Rodrigo
  • Prieto-Nieto, Isabel
  • Domínguez, Gemma
Peritoneal metastasis of colorectal origin appears in ~10-15% of patients at the time of diagnosis and in 30-40% of cases with disease progression. Locoregional spread through the peritoneum is considered stage IVc and is associated with a poor prognosis. The development of a regional therapeutic strategy based on cytoreductive surgery, and hyperthermic intra-abdominal chemotherapy has significantly altered the course of the disease. Although recent evidence supports the benefits of cytoreductive surgery, the benefits of hyperthermic intra-abdominal chemotherapy are, however, still a matter of debate. Understanding the molecular alterations underlying the disease is crucial for developing new therapeutic strategies. Here, we evaluated the involvement in peritoneal dissemination of the oncogenic isoform of TP73, ΔNp73, and its effector targets in in vitro and mouse models, and in 30 patients diagnosed with colorectal peritoneal metastasis. In an orthotopic mouse model, we observed that tumor cells overexpressing ΔNp73 present a higher avidity for the peritoneum and that extracellular vesicles secreted by ΔNp73-upregulating tumor cells enhance their dissemination. In addition, we identified that tumor cells overexpressing ΔNp73 present with dysregulation of genes associated with an epithelial/mesothelial-to-mesenchymal transition (MMT) and that mesothelial cells exposed to the conditioned medium of tumor cells with upregulated ΔNp73 present a mesenchymal phenotype. Lastly, ΔNp73 and its effector target RNAs were dysregulated in our patient series, there were positive correlations between ΔNp73 and its effector targets, and MSN and ITGB4 (ΔNp73 effectors) predicted patient survival. In conclusion, ΔNp73 and its effector targets are involved in the peritoneal dissemination of colorectal cancer and predict patient survival. The promotion of the EMT/MMT and modulation of the adhesion capacity in colorectal cancer cells might be the mechanisms triggered by ΔNp73. Remarkably, ΔNp73 protein is a druggable protein and should be the focus of future studies. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway

  • Lupo,Vincenzo
  • Martínez-Rubio, Dolores
  • Sevilla, Teresa
  • Vílchez, Juan José
  • Palau, Francesc
  • Espinós-Armero, Carmen Ángeles
  • Galindo, Máximo Ibo|||0000-0001-8448-9760
[EN] Mutations in SH3TC2 (KIAA1985) cause Charcot-Marie-Tooth disease (CMT) type 4C, a demyelinating inherited neuropathy characterized by early-onset and scoliosis. Here we demonstrate that the SH3TC2 protein is present in several components of the endocytic pathway including early endosomes, late endosomes and clathrin-coated vesicles close to the trans-Golgi network and in the plasma membrane. Myristoylation of SH3TC2 in glycine 2 is necessary but not sufficient for the proper location of the protein in the cell membranes. In addition to myristoylation, correct anchoring also needs the presence of SH3 and TPR domains. Mutations that cause a stop codon and produce premature truncations that remove most of the TPR domains are expressed as the wild-type protein. In contrast, missense mutations in or around the region of the first-TPR domain are absent from early endosomes, reduced in plasma membrane and late endosomes and are variably present in clathrin-coated vesicles. Our findings suggest that the endocytic and membrane trafficking pathway is involved in the pathogenesis of CMT4C disease. We postulate that missense mutations of SH3TC2 could impair communication between the Schwann cell and the axon causing an abnormal myelin formation., This work was supported by the Fondo de Investigacion Sanitaria [grant numbers PI08/90857, PI08/0889, CP08/00053] and the Spanish Ministry Science and Innovation [grant number SAF2006-01047]. V. L. is a recipient of JAE predoctoral fellowship from the Spanish Scientific Research Council (CSIC). M. I. G. has a `Ramon y Cajal' contract funded by the Ministry of Science and Innovation. C. E. has a `Miguel Servet' contract funded by the Fondo de Investigacion Sanitaria. Both CIBERER and CIBERNED are initiatives from the Instituto de Salud Carlos III. We are grateful to patients and their families for their kind collaboration. We thank B. Alarcón for his technical assistance and also anonymous reviewers for their invaluable insight and suggestions
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Phenotypical features of the p.R120W mutation in the GDAP1 gene causing autosomal dominant Charcot-Marie-Tooth disease

  • Sivera, Rafael
  • Espinós-Armero, Carmen Ángeles
  • Vílchez, Juan J.
  • Mas, Fernando
  • Martínez-Rubio, Dolores
  • Chumillas, María José
  • Mayordomo, Fernando
  • Muelas, Nuria
  • Bataller, Luis
  • Palau, Francesc
  • Sevilla, Teresa
[EN] Mutations in the ganglioside-induced-differentiation-associated protein 1 gene (GDAP1) can cause Charcot-Marie-Tooth (CMT) disease with demyelinating (CMT4A) or axonal forms (CMT2K and ARCMT2K). Most of these mutations present a recessive inheritance, but few autosomal dominant GDAP1 mutations have also been reported. We performed a GDAP1 gene screening in a clinically well-characterized series of 81 index cases with axonal CMT neuropathy, identifying 17 patients belonging to 4 unrelated families in whom the heterozygous p.R120W was found to be the only disease-causing mutation. The main objective was to fully characterize the neuropathy caused by this mutation. The clinical picture included a mild-moderate phenotype with onset around adolescence, but great variability. Consistently, ankle dorsiflexion and plantar flexion were impaired to a similar degree. Nerve conduction studies revealed an axonal neuropathy. Muscle magnetic resonance imaging studies demonstrated selective involvement of intrinsic foot muscles in all patients and a uniform pattern of fatty infiltration in the calf, with distal and superficial posterior predominance. Pathological abnormalities included depletion of myelinated fibers, regenerative clusters and features of axonal degeneration with mitochondrial aggregates. Our findings highlight the relevance of dominantly transmitted p.R120W GDAP1 gene mutations which can cause an axonal CMT with a wide clinical profile., We are grateful to the propositi and their relatives for their kind collaboration. We also want to thank I. Llopis and M. Escutia for their help with sample management. This work was supported by the Instituto de Salud Carlos III [PI08/90857, PI08/0889, CP08/00053 and PS09/00095], the Fundacion para la Investigacion del Hospital Universitari La Fe [CM06/00154], the Spanish Ministry Science and Innovation [grant number SAF2006-01047], and the Generalitat Valenciana [grant no. Prometeo/2009/05]. Dr. C. Espinos has a "Miguel Servet'' contract funded by the Fondo de Investigacion Sanitaria. Both Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER) and Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the Instituto de Salud Carlos III.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Survival motor neuron protein reduction deregulates autophagy in spinal cord motoneurons in vitro

  • Garcera, Ana
  • Bahi i Pla, Núria
  • Periyakaruppiah, Ambika
  • Arumugam, Saravanan
  • Soler i Tatché, Rosa Ma.
Spinal muscular atrophy (SMA) is a genetic disorder characterized by degeneration of spinal cord motoneurons (MNs), resulting in muscular atrophy and weakness. SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene and decreased SMN protein. SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoproteins and pre-mRNA splicing requirements. SMN reduction causes neurite degeneration and cell death without classical apoptotic features, but the direct events leading to SMN degeneration in SMA are still unknown. Autophagy is a conserved lysosomal protein degradation pathway whose precise roles in neurodegenerative diseases remain largely unknown. In particular, it is unclear whether autophagosome accumulation is protective or destructive, but the accumulation of autophagosomes in the neuritic beadings observed in several neurite degeneration models suggests a close relationship between the autophagic process and neurite collapse. In the present work, we describe an increase in the levels of the autophagy markers including autophagosomes, Beclin1 and light chain (LC)3-II proteins in cultured mouse spinal cord MNs from two SMA cellular models, suggesting an upregulation of the autophagy process in Smn (murine survival motor neuron protein)-reduced MNs. Overexpression of Bcl-xL counteracts LC3-II increase, contributing to the hypothesis that the protective role of Bcl-xL observed in some SMA models may be mediated by its role in autophagy inhibition. Our in vitro experimental data indicate an upregulation in the autophagy process and autophagosome accumulation in the pathogenesis of SMA, thus providing a valuable clue in understanding the mechanisms of axonal degeneration and a possible therapeutic target in the treatment of SMA., This work was supported by grants from GENAME (Defining targets for Therapeutics in SMA) to RMS; from Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI11-01047), Generalitat de Catalunya (SGR740) and Consolider-Ingenio 2010 (CSD2007-00020) to RMS. AG holds a post-doctoral contract from Genoma Espan˜a; SA holds a fellowship from Universitat de Lleida and AP holds a fellowship from Comissionat de Universitats i Recerca, Departament d’Innovacio´, Universitats i Empresa de la Generalitat de Catalunya and Fons Social Europeu.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Notch signaling pathway is activated in motoneurons of spinal muscular atrophy

  • Cardona-Rossinyol, Andrea
  • Garcera, Ana
  • Torres-Benito, Laura
  • Soler i Tatché, Rosa Ma.
  • Tabares, Lucía
  • Lladó, Jerònia
  • Olmos, Gabriel
  • Caraballo-Miralles, Víctor
Spinal muscular atrophy (SMA) is a neurodegenerative disease produced by low levels of Survival Motor Neuron (SMN) protein that affects alpha motoneurons in the spinal cord. Notch signaling is a cell-cell communication system well known as a master regulator of neural development, but also with important roles in the adult central nervous system. Aberrant Notch function is associated with several developmental neurological disorders; however, the potential implication of the Notch pathway in SMA pathogenesis has not been studied yet. We report here that SMN deficiency, induced in the astroglioma cell line U87MG after lentiviral transduction with a shSMN construct, was associated with an increase in the expression of the main components of Notch signaling pathway, namely its ligands, Jagged1 and Delta1, the Notch receptor and its active intracellular form (NICD). In the SMNΔ7 mouse model of SMA we also found increased astrocyte processes positive for Jagged1 and Delta1 in intimate contact with lumbar spinal cord motoneurons. In these motoneurons an increased Notch signaling was found, as denoted by increased NICD levels and reduced expression of the proneural gene neurogenin 3, whose transcription is negatively regulated by Notch. Together, these findings may be relevant to understand some pathologic attributes of SMA motoneurons., This work was supported by grants from Fundación Genoma España, GENAME to JL, LT and RMS, and from Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (PI11/01047) to RMS. AG holds a postdoctoral contract from Genoma España. VC-M and AC-R have been supported by a predoctoral fellowship from “Govern de les Illes Balears, Conselleria d’Educació, Cultura i Universitats” under a program of joint financing with the European Social Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Notch signaling pathway is activated in motoneurons of spinal muscular atrophy

  • Cardona-Rossinyol, Andrea
  • Garcera, Ana
  • Torres-Benito, Laura
  • Soler i Tatché, Rosa Ma.
  • Tabares, Lucía
  • Lladó, Jerònia
  • Olmos, Gabriel
  • Caraballo-Miralles, Víctor
Spinal muscular atrophy (SMA) is a neurodegenerative disease produced by low levels of Survival Motor Neuron (SMN) protein that affects alpha motoneurons in the spinal cord. Notch signaling is a cell-cell communication system well known as a master regulator of neural development, but also with important roles in the adult central nervous system. Aberrant Notch function is associated with several developmental neurological disorders; however, the potential implication of the Notch pathway in SMA pathogenesis has not been studied yet. We report here that SMN deficiency, induced in the astroglioma cell line U87MG after lentiviral transduction with a shSMN construct, was associated with an increase in the expression of the main components of Notch signaling pathway, namely its ligands, Jagged1 and Delta1, the Notch receptor and its active intracellular form (NICD). In the SMNΔ7 mouse model of SMA we also found increased astrocyte processes positive for Jagged1 and Delta1 in intimate contact with lumbar spinal cord motoneurons. In these motoneurons an increased Notch signaling was found, as denoted by increased NICD levels and reduced expression of the proneural gene neurogenin 3, whose transcription is negatively regulated by Notch. Together, these findings may be relevant to understand some pathologic attributes of SMA motoneurons., This work was supported by grants from Fundación Genoma España, GENAME to JL, LT and RMS, and from Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (PI11/01047) to RMS. AG holds a postdoctoral contract from Genoma España. VC-M and AC-R have been supported by a predoctoral fellowship from “Govern de les Illes Balears, Conselleria d’Educació, Cultura i Universitats” under a program of joint financing with the European Social Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Survival motor neuron protein reduction deregulates autophagy in spinal cord motoneurons in vitro

  • Garcera, Ana
  • Bahi i Pla, Núria
  • Periyakaruppiah, Ambika
  • Arumugam, Saravanan
  • Soler i Tatché, Rosa Ma.
Spinal muscular atrophy (SMA) is a genetic disorder characterized by degeneration of spinal cord motoneurons (MNs), resulting in muscular atrophy and weakness. SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene and decreased SMN protein. SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoproteins and pre-mRNA splicing requirements. SMN reduction causes neurite degeneration and cell death without classical apoptotic features, but the direct events leading to SMN degeneration in SMA are still unknown. Autophagy is a conserved lysosomal protein degradation pathway whose precise roles in neurodegenerative diseases remain largely unknown. In particular, it is unclear whether autophagosome accumulation is protective or destructive, but the accumulation of autophagosomes in the neuritic beadings observed in several neurite degeneration models suggests a close relationship between the autophagic process and neurite collapse. In the present work, we describe an increase in the levels of the autophagy markers including autophagosomes, Beclin1 and light chain (LC)3-II proteins in cultured mouse spinal cord MNs from two SMA cellular models, suggesting an upregulation of the autophagy process in Smn (murine survival motor neuron protein)-reduced MNs. Overexpression of Bcl-xL counteracts LC3-II increase, contributing to the hypothesis that the protective role of Bcl-xL observed in some SMA models may be mediated by its role in autophagy inhibition. Our in vitro experimental data indicate an upregulation in the autophagy process and autophagosome accumulation in the pathogenesis of SMA, thus providing a valuable clue in understanding the mechanisms of axonal degeneration and a possible therapeutic target in the treatment of SMA., This work was supported by grants from GENAME (Defining targets for Therapeutics in SMA) to RMS; from Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI11-01047), Generalitat de Catalunya (SGR740) and Consolider-Ingenio 2010 (CSD2007-00020) to RMS. AG holds a post-doctoral contract from Genoma Espan˜a; SA holds a fellowship from Universitat de Lleida and AP holds a fellowship from Comissionat de Universitats i Recerca, Departament d’Innovacio´, Universitats i Empresa de la Generalitat de Catalunya and Fons Social Europeu.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Activity of Antibiotics and Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium-intracellulare Complex Causing Chronic Pulmonary Infections

  • Portell Buj, Elena|||0000-0003-1286-5303
  • González-Criollo, Cecibel
  • López-Gavín, Alexandre|||0000-0001-6996-0227
  • Fernandez-Pittol, Mariana|||0000-0002-1685-7127
  • Busquets, M. Antònia|||0000-0002-6232-9886
  • Estelrich i Latràs, Joan|||0000-0002-1373-3671
  • Garrigo, Montserrat|||0000-0003-4431-4733
  • Rubio, Marc|||0000-0002-4811-0642
  • Tudó, Griselda|||0000-0002-9241-7051
  • Gonzalez-Martin, Julian|||0000-0001-7248-6706
Nontuberculous mycobacteria (NTM) cause lung infections in patients with underlying pulmonary diseases (PD). The Mycobacterium avium-intracellulare complex (MAC) is the most frequently involved NTM. The MAC-PD treatment is based on the administration of several antibiotics for long periods of time. Nonetheless, treatment outcomes remain very poor. Among the factors involved is the ability of MAC isolates to form biofilm. The aim of the study was to assess the in vitro activity of different antibiotics and potential antibiofilm agents (PAAs) against MAC biofilm. Four antibiotics and six PAAs, alone and/or in combination, were tested against planktonic forms of 11 MAC clinical isolates. Biofilm was produced after 4 weeks of incubation and analyzed with the crystal violet assay. The antibiotics and PAAs were tested by measuring the absorbance (minimum biofilm inhibition concentrations, MBICs) and by performing subcultures (minimum biofilm eradication concentrations, MBECs). The clarithromycin/amikacin and clarithromycin/ethambutol combinations were synergistic, decreasing the MBECs values compared to the individual antibiotics. The amikacin/moxifloxacin combination showed indifference. The MBIC values decreased significantly when PAAs were added to the antibiotic combinations. These results suggest that antibiotic combinations should be further studied to establish their antibiofilm activity. Moreover, PAAs could act against the biofilm matrix, facilitating the activity of antibiotics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium and Mycobacterium intracellulare Clinical Isolates

  • Batista, Sara
  • Fernandez-Pittol, Mariana|||0000-0002-1685-7127
  • San Nicolás, Lorena
  • Martínez, Diego
  • Rubio, Marc|||0000-0002-4811-0642
  • Garrigo, Montserrat|||0000-0003-4431-4733
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Tudó, Griselda|||0000-0002-9241-7051
  • Gonzalez-Martin, Julian|||0000-0001-7248-6706
Patients with chronic pulmonary diseases infected by Mycobacterium avium complex (MAC) often develop complications and suffer from treatment failure due to biofilm formation. There is a lack of correlation between in vitro susceptibility tests and the treatment of clinical isolates producing biofilm. We performed susceptibility tests of 10 different three-drug combinations, including two recommended in the guidelines, in biofilm forms of eight MAC clinical isolates. Biofilm developed in the eight isolates following incubation of the inoculum for 3 weeks. Then, the biofilm was treated with three-drug combinations with and without the addition of potential antibiofilm agents (PAAs). Biofilm bactericidal concentrations (BBCs) were determined using the Vizion lector system. All selected drug combinations showed synergistic activity, reducing BBC values compared to those treated with single drugs, but BBC values remained high enough to treat patients. However, with the addition of PAAs, the BBCs steadily decreased, achieving similar values to the combinations in planktonic forms and showing synergistic activity in all the combinations and in both species. In conclusion, three-drug combinations with PAAs showed synergistic activity in biofilm forms of MAC isolates. Our results suggest the need for clinical studies introducing PAAs combined with antibiotics for the treatment of patients with pulmonary diseases infected by MAC.